Article Text

Download PDFPDF
Extended report
Development of a simple prognostic nomogram for individualising 5-year and 10-year absolute risks of fracture: a population-based prospective study among postmenopausal women
  1. Tineke A C M van Geel1,
  2. Nguyen D Nguyen2,
  3. Piet P Geusens3,
  4. Jacqueline R Center2,
  5. Tuan V Nguyen2,
  6. Geert-Jan Dinant1,
  7. John A Eisman2
  1. 1Department of General Practice, Maastricht University/Caphri School for Public Health and Primary Care, Maastricht, The Netherlands
  2. 2Garvan Institute of Medical Research, Osteoporosis and Bone Biology Program, Sydney, Australia
  3. 3Department of Internal Medicine, Maastricht University Medical Centre/Caphri School for Public Health and Primary Care, Maastricht, The Netherlands
  1. Correspondence to Tineke A C M van Geel, Department of General Practice, Maastricht University/Caphri School for Public Health and Primary Care, PO Box 616, 6200 MD Maastricht, The Netherlands; t.vangeel{at}hag.unimaas.nl

Footnotes

  • Funding This project was supported by grants from Maastricht University. All researchers are independent from funders in regards to this study.

  • Competing interests JAE (consulting fees or other remuneration): Amgen, Decode, Eli Lilly, Ge-Lunar, Merck Sharp & Dohme, Novartis, Roche-GSK, Sanofi-Aventis, Servier and Wyeth Australia. PPG (consulting fees or other remuneration): Amgen, Eli Lilly, Ge-Lunar, Merck Sharp & Dohme, Novartis, Roche-GSK, Sanofi-Aventis, Servier, Wyeth, Schering Plough, Abbott, Pfizer. Other authors: none.

  • Ethics approval This study was conducted with the approval of the Ethical Review Committee of Maastricht University and the Maastricht University Hospital (reference number MEC 94-196.1). Written informed consent forms were obtained from all participants.

  • Provenance and peer review Not commissioned; externally peer reviewed.

View Full Text

Statistics from Altmetric.com

Footnotes

  • Funding This project was supported by grants from Maastricht University. All researchers are independent from funders in regards to this study.

  • Competing interests JAE (consulting fees or other remuneration): Amgen, Decode, Eli Lilly, Ge-Lunar, Merck Sharp & Dohme, Novartis, Roche-GSK, Sanofi-Aventis, Servier and Wyeth Australia. PPG (consulting fees or other remuneration): Amgen, Eli Lilly, Ge-Lunar, Merck Sharp & Dohme, Novartis, Roche-GSK, Sanofi-Aventis, Servier, Wyeth, Schering Plough, Abbott, Pfizer. Other authors: none.

  • Ethics approval This study was conducted with the approval of the Ethical Review Committee of Maastricht University and the Maastricht University Hospital (reference number MEC 94-196.1). Written informed consent forms were obtained from all participants.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.